BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24843314)

  • 1. Trefoil factor 1 in early breast carcinoma: a potential indicator of clinical outcome during the first 3 years of follow-up.
    Markićević M; Džodić R; Buta M; Kanjer K; Mandušić V; Nešković-Konstantinović Z; Nikolić-Vukosavljević D
    Int J Med Sci; 2014; 11(7):663-73. PubMed ID: 24843314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytosolic levels of TFF1/pS2 in breast cancer: Their relationship with clinical-pathological parameters and their prognostic significance.
    Corte MD; Tamargo F; Alvarez A; Rodríguez JC; Vázquez J; Sánchez R; Lamelas ML; González LO; Allende MT; García-Muñiz JL; Fueyo A; Vizoso F
    Breast Cancer Res Treat; 2006 Mar; 96(1):63-72. PubMed ID: 16267614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytosolic levels of an estrogen-induced breast cancer-associated peptide (TFF1/pS2) in colorectal cancer: clinical significance and relationship with steroid receptors.
    Vizoso FJ; Fagilde MC; Corte MD; Corte MG; Gava R; Bongera M; Allende MT; García-Muñiz JL
    Int J Biol Markers; 2003; 18(4):301-10. PubMed ID: 14756547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
    Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
    Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive value of TFF1 for adjuvant endocrine therapy in Chinese women with early ER positive breast cancer: comparing aromatase inhibitors with tamoxifen.
    Zhou L; Yan T; Jiang Y; Di G; Shen Z; Shao Z; Lu J
    Breast; 2011 Feb; 20(1):15-20. PubMed ID: 20619646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
    Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
    Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers.
    Gillesby BE; Zacharewski TR
    Breast Cancer Res Treat; 1999 Aug; 56(3):253-65. PubMed ID: 10573116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary mucinous carcinomas of the skin express TFF1, TFF3, estrogen receptor, and progesterone receptors.
    Hanby AM; McKee P; Jeffery M; Grayson W; Dublin E; Poulsom R; Maguire B
    Am J Surg Pathol; 1998 Sep; 22(9):1125-31. PubMed ID: 9737246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen-regulated cut-off values of pS2 and cathepsin D expression in breast carcinomas.
    Markićević M; Petrović A; Kanjer K; Nesković-Konstantinović Z; Nikolić-Vukosavujević D
    Adv Exp Med Biol; 2008; 617():341-8. PubMed ID: 18497057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
    Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
    Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
    Bardou VJ; Arpino G; Elledge RM; Osborne CK; Clark GM
    J Clin Oncol; 2003 May; 21(10):1973-9. PubMed ID: 12743151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive of 21-gene recurrence score assay in non-estrogen receptor-positive and lymph node-negative breast cancer.
    Lu K; Li H; Wu Z; Liu D; Ye H; Xu L; Liu Y
    J BUON; 2018; 23(5):1297-1301. PubMed ID: 30570850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors for Survival and Distribution of 21-Gene Recurrence Score in Patients With Pure Mucinous Breast Cancer: A SEER Population-Based Retrospective Analysis.
    Ding S; Wu J; Lin C; Chen W; Li Y; Shen K; Zhu L
    Clin Breast Cancer; 2019 Feb; 19(1):e66-e73. PubMed ID: 30396812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
    Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
    Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy.
    Takei H; Horiguchi J; Maemura M; Koibuchi Y; Oyama T; Yokoe T; Iino Y; Morishita Y
    Oncol Rep; 2002; 9(2):375-8. PubMed ID: 11836611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid receptor status and its clinicopathological correlation in post-menopausal breast cancer patients of Kumaon region of Uttarakhand.
    Shahi KS; Bhandari G; Singh A
    J Cancer Res Ther; 2011; 7(1):19-22. PubMed ID: 21546737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.